Corporate Announcements - China Aluminum announced the election of He Wenjian as chairman and the appointment of Zhang Ruizhong as general manager, with Zhang holding 147,100 shares of A-shares [4] - Jiangbolong reported that its self-developed main control chip deployment exceeded 100 million units by the end of Q3, with ongoing rapid growth [5] - Asia-Pacific Pharmaceutical received a notice of disapproval for the consistency evaluation application of Diltiazem Hydrochloride Tablets, which will not significantly impact current performance [6] - Fuxiang Pharmaceutical successfully passed the FDA's cGMP inspection, marking the third successful inspection, enhancing its qualification for international market supply [7] - Biaobang Co. terminated its control change planning due to failure to reach consensus on core terms, leading to stock resumption [8] - Jingjin Equipment announced the release of its actual controller and chairman from detention, allowing normal operations [9] - Sand Membrane reported that part of its fundraising account was frozen, amounting to 11.74 million yuan, related to a contract dispute [10] - Renfu Pharmaceutical's subsidiary received approval for clinical trials of HWH217 tablets for treating pulmonary arterial hypertension [12] - Wanye Enterprises will change its stock name to "Xian Dao Ji Dian" effective November 12 [13] - Huahai Pharmaceutical's subsidiary passed the FDA inspection, ensuring compliance with international standards [14] Performance Metrics - Daqin Railway reported a cargo transport volume of 32.51 million tons in October, a decrease of 4.7% year-on-year [19] - Jingji Agriculture announced sales of 233,300 pigs in October, generating revenue of 317 million yuan [20] - Baiyun Airport reported a passenger throughput of 7.64 million in October, a year-on-year increase of 12.04% [21] - Dongfeng Motor's total vehicle production decreased by 23.4% year-on-year in October, with significant declines in commercial vehicle categories [22] - Hongyang Real Estate reported a contract sales amount of 202 million yuan in October [23][24] Shareholding Changes - Xintonglian announced that a shareholder plans to reduce its stake by up to 3% [25] - Tonghua Dongbao conducted its first share buyback, acquiring 0.01% of its shares for 1.29 million yuan [26] - Guoci Materials plans to repurchase shares worth 100 million to 200 million yuan at a price not exceeding 30 yuan per share [27] - Xili Technology announced multiple shareholders plan to reduce their stakes [28] Major Contracts - Dayu Water announced a pre-bid win for a 310 million yuan water conservancy project in Hainan [29] - Zhongjian Technology signed a significant sales contract worth 563 million yuan [30] - Longjian Co. won a bid for a 441 million yuan project for road construction in Heilongjiang [31] - Chongqing Construction's subsidiary won a bid for a 781 million yuan project in Chongqing [32]

Core Viewpoint - Tonghua Dongbao announced a share buyback plan, indicating confidence in its stock value and commitment to returning capital to shareholders [1] Group 1 - The company will repurchase a total of 143,500 shares [1] - This repurchase represents 0.01% of the company's current total share capital [1] - The buyback will be conducted through centralized bidding trading [1]

Corporate Governance - China Aluminum announced the election of He Wenjian as chairman and the appointment of Zhang Ruizhong as general manager, effective immediately [3] - Jiang Guiting, the actual controller and chairman of Jingjin Equipment, has had his detention lifted, allowing him to resume his duties [8] - Biao Bang Co. has terminated its plans for a change in control, with stock resuming trading [7] Industry Developments - Jiangbolong reported that its self-developed main control chip deployment has exceeded 100 million units, with rapid growth expected [4] - Asia Pacific Pharmaceutical received a notice of disapproval for its consistency evaluation application for a drug, which will not significantly impact its current performance [5] - Fuxiang Pharmaceutical successfully passed a cGMP inspection by the FDA, marking its third successful inspection [6] - Huahai Pharmaceutical's subsidiary passed an FDA inspection, enhancing its international market capabilities [13] Financial Performance - Daqin Railway reported a cargo transport volume of 32.51 million tons in October 2025, a year-on-year decrease of 4.7% [18] - Jingji Zhino achieved sales revenue of 317 million yuan from selling 233,300 pigs in October 2025 [19] - Baiyun Airport reported a passenger throughput of 7.64 million in October 2025, a year-on-year increase of 12.04% [20] - Dongfeng Motor's total vehicle production in October 2025 was 6,536 units, a year-on-year decrease of 23.40% [21] - Hongyang Real Estate reported a contract sales amount of 202 million yuan in October 2025 [22] Shareholder Actions - Xintonglian announced that a shareholder plans to reduce its stake by up to 3% [24] - Tonghua Dongbao conducted its first share buyback, acquiring 143,500 shares for 1.29 million yuan [25] - Guoci Materials plans to repurchase shares worth 100 million to 200 million yuan at a price not exceeding 30 yuan per share [26] Project Wins - Dayu Water-saving announced a pre-bid win for a 310 million yuan water conservancy project in Hainan [28] - Zhongjian Technology signed a significant sales contract worth 563 million yuan [29] - Longjian Co. won a project bid worth 441 million yuan for road construction in Heilongjiang [30] - Chongqing Construction's subsidiary won a project bid worth 781 million yuan for a residential project in Chongqing [31]

Group 1 - Company announced a share repurchase of approximately 140,000 shares, representing 0.01% of the total share capital, at a price range of 9 CNY per share, with a total transaction amount of approximately 1.29 million CNY [1] - For the first half of 2025, the company's revenue composition was 98.59% from the pharmaceutical industry, 1.27% from other businesses, and 0.14% from the real estate sector [1] - The current market capitalization of the company is 17.7 billion CNY [1]

Group 1 - The company, Tonghua Dongbao (600867.SH), announced its first share repurchase on November 6, 2025, through centralized bidding [1] - A total of 143,500 shares were repurchased, accounting for 0.01% of the company's current total share capital [1] - The highest and lowest transaction prices for the repurchase were both 9.00 yuan per share, with a total transaction amount of 1.2915 million yuan (excluding transaction fees) [1]

通化东宝公告，公司于2025年11月6日首次通过集中竞价交易方式回购公司股份，累计回购股数为14.35 万股，占公司总股本的0.01%，累计回购金额为129.15万元，实际回购价格为9元/股。此次回购将用于 员工持股计划或股权激励。 ...

Company Overview - Tonghua Dongbao Pharmaceutical Co., Ltd. is located in Tonghua County, Jilin Province, established on December 28, 1992, and listed on August 24, 1994 [1] - The company's main business includes hard capsule preparations, tablets (including hormone types), granules, small-volume injections, raw materials (recombinant human insulin), and biological engineering products (recombinant human insulin injection) [1] Financial Performance - For the period from January to September 2025, Tonghua Dongbao achieved operating revenue of 2.18 billion yuan, a year-on-year increase of 50.55% [2] - The net profit attributable to the parent company was 1.20 billion yuan, showing a significant year-on-year growth of 1911.35% [2] Stock Market Activity - As of November 4, the stock price of Tonghua Dongbao was 9.08 yuan per share, with a market capitalization of 17.78 billion yuan [1] - The stock has increased by 16.23% year-to-date, with a 2.02% rise over the last five trading days and a 9.79% increase over the last 20 days [1] Shareholder Information - As of September 30, 2025, the number of shareholders was 82,100, a decrease of 5.08% from the previous period [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which increased its holdings by 15.84 million shares [3] Dividend Distribution - Since its A-share listing, Tonghua Dongbao has distributed a total of 5.51 billion yuan in dividends, with 1.48 billion yuan distributed in the last three years [3]

Core Points - The company held its third extraordinary general meeting of shareholders on November 3, 2025, with no resolutions being rejected [2][5] - The meeting was convened by the board of directors and chaired by Chairman Li Jiahong, utilizing a combination of on-site and online voting methods [2][5] Group 1: Meeting Details - The meeting was attended by all nine current directors and three supervisors, with the presence of senior management [3][4] - Several governance-related proposals were passed, including the cancellation of the supervisory board and amendments to the company's articles of association [3][4] - The voting results were deemed legal and valid, in compliance with relevant laws and regulations [5] Group 2: Board Changes - Director Zhang Guodong submitted a resignation letter due to internal work adjustments but will continue as the company's deputy general manager [8][9] - Zhang Guodong was elected as a representative director of the employee board during the ninth fourth employee representative conference held on November 3, 2025 [8][10] - His resignation does not affect the minimum number of board members required by law and will not disrupt the normal operations of the board [9][10] Group 3: Director Profile - Zhang Guodong, born in August 1976, holds a bachelor's degree in clinical medicine and an MBA [12] - He has a history of working in the pharmaceutical industry, including roles at Federal Pharmaceuticals and Eli Lilly, before joining the company in 2005 [12] - As of the announcement date, he holds 264,120 shares of the company, representing 0.01% of the total share capital [12]

Core Viewpoint - Tonghua Dongbao announced the election of Mr. Zhang Guodong as the employee representative director for the 11th board of directors during the 4th employee representative assembly scheduled for November 3, 2025 [2] Group 1 - The 9th Fourth Employee Representative Assembly will be held on November 3, 2025 [2] - Mr. Zhang Guodong has been elected as the employee representative director [2]

证券代码：600867 证券简称：通化东宝 公告编号：2025-077 通化东宝药业股份有限公司 关于公司董事辞职暨选举职工代表董事的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 通化东宝药业股份有限公司（以下简称"公司"）董事会近日收到董事张国 栋先生递交的书面辞职报告，因公司内部工作调整，张国栋先生申请辞去公司董 事的职务。辞职后，张国栋先生继续担任公司副总经理职务。 2025 年 11 月 3 日，公司召开第九届第四次职工代表大会，同意选举张国栋 先生为公司第十一届董事会职工代表董事，任期自公司职工代表大会选举之日起 至公司第十一届董事会任期届满之日止。 一、董事辞职情况 (一) 基本情况 | 姓名 | 离任 职务 | 离任时间 | 原定任期到期日 | 离任 原因 | 是否继续 在上市公 司及其控 股子公司 任职 | 具体职务 | 是否存在 未履行完 毕的公开 承诺 | | --- | --- | --- | --- | --- | --- | --- | --- | | 张国栋 | 董事 | 2 ...